期刊文献+

老年上皮性卵巢癌组织中磷酸化AKT和P-gp表达与化疗反应及预后的关系 被引量:2

Correlation between the expressions of p-AKT,P-gp and chemotherapy effects and prognosis in epithelial ovarian cancer tissue
下载PDF
导出
摘要 目的探讨老年上皮性卵巢癌组织中磷酸化-AKT(p-AKT)和P-糖蛋白(P-gp)表达与卵巢癌化疗反应及预后的关系。方法采用免疫组化SP法检测63例上皮性卵巢癌组织和20例正常卵巢组织中p-AKT和P-gp表达,分析其与化疗反应的关系,同时对预后进行多因素的Cox生存分析。结果p-AKT和P-gp在上皮性卵巢癌组织中阳性表达率分别为52.4%和31.7%,显著高于正常卵巢组织(P<0.01),且p-AKT和P-gp表达存在相关性。p-AKT和P-gp表达阳性组的化疗反应率显著高于p-AKT和P-gp表达阴性组(P<0.001)。多因素生存分析显示,年龄≥60岁、手术病理分期、术后残留灶直径≥2cm是影响患者预后的独立危险因素。结论p-AKT和P-gp阳性表达与上皮性卵巢癌组织化疗耐药有关,p-AKT过表达对P-gp阳性表达可能具有促进作用,在卵巢癌化疗耐药中起重要作用,对合理制定化疗方案、预测化疗反应性及估计预后具有积极的指导意义。 Objective To investigate the relationship between the expressions of phosphorylation AKT( p-AKT), P-gp and chemotherapy effects and prognosis in eldly epithelial ovarian cancer tissue. Methods The expressions of p-AKT and P-gp in 63 ovarian cancer tissues and 20 normal ovarian tissues were tested by immunohistochemistry. Results The positive rates of p-AKT ( 52.4% ) and P-gp (31.7%) in ovarian cancer tissue were higher than those in normal ovarian tissue( P 〈 0. 01 ), and there was positive correlation between p- AKT and P-gp. The chemotherapy reaction rates of p-AKT and P-gp positive groups were higher than those of p-AKT and P-gp negative groups (P 〈 0. 001 ) . Aging( ≥60 years old) , pathologic stage and diameter of surgery focal residual ≥2 cm were independent risk factors influencing prognosis. Conclusions The expressions of p-AKT and P-gp are related with drug fast of epithelial ovarian cancer chemotherapy. The overexpression of p-AKT may promote the expression of P-gp.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2009年第6期706-709,共4页 Chinese Journal of Gerontology
基金 吉林省科技厅国际合作(20070729-20) 吉林省科技厅国际合作项目(20070729-2) 吉林省科技厅重点项目(20082102)
关键词 卵巢肿瘤 磷酸化-AKT P-糖蛋白 化学疗法 Ovarian cancer p-AKT P-gp Chemotherapy
  • 相关文献

参考文献16

  • 1Page C,Lin HJ,Jin Y,et al.Overexpression of AKT/AKT can modulate chemotherapy-induced apoptosis〔J〕.Anticancer Res,2000;20(1A):407-16.
  • 2Holschneider CH,Berek JS.Ovarian cancer:epidemiology,biology,and prognostic factors〔J〕.Semin Surg Oncol,2000;19(1):3-10.
  • 3Mayr D,Pannekamp U,Baretton GB,et al.Immunohistochemical analysis of drug resistance associated protein in ovarian carcinomas〔J〕.Pathol Res Pract,2000;196(7):469-75.
  • 4Jemal A,Thomas A,Murray T,et al.Cancer statistics〔J〕.CA Cancer J Clin,2002;52(1):23-47.
  • 5连利娟,刘彤华,刘炽明,等.妇科肿瘤学〔M〕.北京:人民卫生出版社,2000:4832-3.
  • 6Basaki Y,Hosoi F,Oda Y,et al.AKT-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells〔J〕.Oncogene,2007;26(19):2736-46.
  • 7Lee S,Choi EJ,Jin C,et al.Activation of PI3K/AKT pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line〔J〕.Gynecol Oncol,2005;97(1):26-34.
  • 8Fraser M,Leung BM,Yan X,et al.p53 is a determinant of X-linked inhibitor of apoptosis protein/AKT-mediated chemoresistance in human ovarian cancer cells〔J〕.Cancer Res,2003;63(21):7081-8.
  • 9Qiu L,Di W,Jiang Q,et al.Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death〔J〕.Int J Oncol,2005;27(5):1441-8.
  • 10Westfall SD,Skinner MK.Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment〔J〕.Mol Cancer Ther,2005;4(11):1764-71.

同被引文献18

  • 1褚艳侠,郑艾.上皮性卵巢癌生物学预后相关因素[J].西部医学,2006,18(3):371-373. 被引量:1
  • 2du Bois A, Reuss A, Pujade - Lauraine E, etal. Role of surgi- cal outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively ran- domized phase 3 multicenter trials [J]. Cancer, 2009, 115(6): 1234-1244.
  • 3Janssen-Heijnen M L G, Gondos A, Bray F, etal. Clinical rele- vance of conditional survival of cancer patients in Europe: age- specific analyses of 13 cancers [J]. Journal of Clinical Oncology, 2010, 28(15): 2520-2528.
  • 4Mackay H J, Brady M F, Oza A M, etal. Prognostic relevance of uncommon ovarian histology in women with stage Ⅲ/Ⅳ epi- thelial ovarian cancer [J]. International journal of gynecological cancer, 2010, 20(6): 945-952.
  • 5Jorgensen T L, Teiblum S, Paludan M, et al. Significance of age and comorbidity on treatment modality, treatment adher- ence, and prognosis in elderly ovarian cancer patients I-J]. Gy- necologic oncology, 2012, 2(14) : 74-79.
  • 6王志梅,张凡,张九鸿,等.老年卵巢癌MGMT,GST-Ⅱ,HIF-1⒈表达与临床预后关系的组织芯片研究[J].中国美容医学,2011,20(4):314-319.
  • 7Jorgensen T L, Teiblum S, Paludan M et al. Significance of age and eomorbidity on treatment modality, treatment adher- ence, and prognosis in elderly ovarian cancer patients [J]. Gy- necologic oneology, 2012, 25(3) 322-328.
  • 8Ueda T, Volinia S, Okumura H, et al. Relation between mi- croRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis [J]. The lancet oncolo- gy, 2010, 11(2): 136-146.
  • 9Rustin GJ S, van der Burg M E L, Griffin C L, etal. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955)z a randomised trial [J]. The Lancet, 2010, 376(9747): 1155-1163.
  • 10Trine Lembrecht J?rgensen,Sandra Teiblum,Merete Paludan,Laurids ?stergaard Poulsen,Anni Young Stensg?rd J?rgensen,Karin Herskind Bruun,Jesper Hallas,J?rn Herrstedt.Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients[J].Gynecologic Oncology.2012(2)

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部